Gautham Marigowda
Overview
Explore the profile of Gautham Marigowda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
3072
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Konstan M, McKone E, Moss R, Marigowda G, Tian S, Waltz D, et al.
Lancet Respir Med
. 2016 Dec;
5(2):107-118.
PMID: 28011037
Background: The 24-week safety and efficacy of lumacaftor/ivacaftor combination therapy was shown in two randomised controlled trials (RCTs)-TRAFFIC and TRANSPORT-in patients with cystic fibrosis who were aged 12 years or...
12.
Rowe S, McColley S, Rietschel E, Li X, Bell S, Konstan M, et al.
Ann Am Thorac Soc
. 2016 Nov;
14(2):213-219.
PMID: 27898234
Rationale: In a prior study, lumacaftor/ivacaftor treatment (≤28 d) in patients with cystic fibrosis (CF) heterozygous for F508del-CFTR did not improve lung function. Objectives: To evaluate an optimized lumacaftor/ivacaftor dosing...
13.
Marigowda G, Liu F, Waltz D
J Cyst Fibros
. 2016 Nov;
16(2):246-249.
PMID: 27894875
In an open-label, single-center phase 1 pharmacokinetic study in healthy subjects who received lumacaftor (LUM) in combination with ivacaftor (IVA), review of spirometry data showed a transient decline in percent...
14.
Milla C, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M
Am J Respir Crit Care Med
. 2016 Nov;
195(7):912-920.
PMID: 27805836
Rationale: Combination lumacaftor/ivacaftor has been shown to improve lung function and other endpoints in patients aged 12 years and older with cystic fibrosis and homozygous for F508del-CFTR, but it has...
15.
Elborn J, Ramsey B, Boyle M, Konstan M, Huang X, Marigowda G, et al.
Lancet Respir Med
. 2016 Jun;
4(8):617-626.
PMID: 27298017
Background: Lumacaftor/ivacaftor combination therapy has shown clinical benefits in patients with cystic fibrosis homozygous for the Phe508del CFTR mutation; however, pretreatment lung function is a confounding factor that potentially affects...
16.
Wainwright C, Elborn J, Ramsey B, Marigowda G, Huang X, Cipolli M, et al.
N Engl J Med
. 2015 May;
373(3):220-31.
PMID: 25981758
Background: Cystic fibrosis is a life-limiting disease that is caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) protein activity. Phe508del is the most common CFTR mutation. Methods:...
17.
Kazani S, Planaguma A, Ono E, Bonini M, Zahid M, Marigowda G, et al.
J Allergy Clin Immunol
. 2013 Apr;
132(3):547-553.
PMID: 23608729
Background: The relationship between anti-inflammatory lipoxins and proinflammatory leukotrienes might be important in the pathobiology and severity of asthma. Objective: We sought to investigate whether exhaled breath condensate (EBC) lipoxin...
18.
Wechsler M, Kelley J, Boyd I, Dutile S, Marigowda G, Kirsch I, et al.
N Engl J Med
. 2011 Jul;
365(2):119-26.
PMID: 21751905
Background: In prospective experimental studies in patients with asthma, it is difficult to determine whether responses to placebo differ from the natural course of physiological changes that occur without any...
19.
Kim S, Marigowda G, Oren E, Israel E, Wechsler M
J Allergy Clin Immunol
. 2010 Jun;
125(6):1336-43.
PMID: 20513524
Background: Treatments for Churg-Strauss syndrome (CSS), a rare eosinophilic vasculitis characterized by asthma, sinusitis, peripheral eosinophilia, pulmonary infiltrates, and tissue infiltration, are limited by toxicity or poor efficacy. Levels of...
20.
Matangkasombut P, Marigowda G, Ervine A, Idris L, Pichavant M, Kim H, et al.
J Allergy Clin Immunol
. 2009 Apr;
123(5):1181-5.
PMID: 19356791
No abstract available.